Indinavir (Sulphate)

Also known as: Sulfatoindinavir

Drug #1468

Indinavir (Sulphate) is a protease inhibitor with antiretroviral activity. Indinavir (Sulphate) is used in combintion with other antiretroviral agents for the treatment of HIV infection and with advanced ae progressive immunedefiency.

← Previous drug Next drug →

Primary Characteristics

Indinavir (Sulphate) is also known as Sulfatoindinavir.

It is of Synthetic origin and belongs to Indanes, pherylpropylamine.

Molecular Weight: 711.9 · pK_a: 6.2 · Solubility in Water: > 1 in 10 · Non-proprietary name: Indinavir (Sulphate).

Molecular structure of Indinavir (Sulphate)

Pharmacokinetics

Absorption: Indinavir (Sulphate) has an oral bioavailability is 19% (±1%).

Distribution: Indinavir (Sulphate) has a volume of distribution is 2.8. plasma protein binding is 60%.

Elimination: plasma half-life is 1.8±0.4 hr, renal excretion is < 20% (unchanged/Metabolites).

Indications

Indinavir (Sulphate) is primarily indicated in conditions like AIDS, HIV infection.

Indinavir (Sulphate) is also indicated for secondary conditions like Prophylaxis after occupational exposure to HIV.

Contraindications

Indinavir (Sulphate) is contraindicated in conditions like Diabetes mellitus, Haemophilia, Hypersensitivity.

Dosage

Indinavir (Sulphate)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
500 mg	500 mg	Every 8h	Adolescence
600 mg	600 mg	Every 8h	Hepatic insuffiency
800 mg	800 mg	Every 8h	PO
Paediatric Dosage (20kg)
500 mg/m2	500 mg/m2	Every 8h	PO	child under 4 year safety not establish
800 mg/m2	800 mg/m2	Every 8h	PO	Child 4-7 year,
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown10 interactions

8 interactions

Major5 interactions

Minor1 interaction

Moderate2 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Indinavir (Sulphate) in overdosage may give rise to further complications which include Nausea , Vomiting , Anorexia , Hyperglycemia , Diarrhea, Renal stones , Hyperglycemia, Renal insufficiency, Diabetes mellitus.

Indinavir (Sulphate) produces potentially life-threatening effects which include Anemia, Thrombocytopenia , Bleeding , Anemia, Skin hematomas, Acute hemolytic anemia, Hemarthrosis, Hemarthrosis. Careful monitoring is needed with proper medical management.

Indinavir (Sulphate) is known to cause more or less tolerable side effects which are usually transient. These include Abdominal distension, Acute renal failure, Crystalluria , Hematuria, Hepatic failure, Hepatitis, Hyperbilirubinemia, Hypercholesterolemia, Hyperpigmentation , Hypertriglyceridemia, Liver dysfunction, Nephrolithiasis including flank pain, Proteinuria , Weight LossX.

Warnings / Precautions

Caution is required in diabetic patient, patients with hemophilia who may experienced increased bleeding . Indinavir should be used with caution and possible dose reduction is needed in hepatic impairment. Adequate hydration is recommended to avoid any risk of nephrolithiasis. Monitoring is required in case of renal impairment. Avoid in porphyrid hepatic impairment , Preexisting livered disease or chronic hepatitis B&C treatment may need to be stopped or temperature interupted in patient developing nephrolithasis cuation in a eating pateint with hemeophilis A&B as report of spotaneous Bleeding with use of HIV use of the HIV protease inhibitor

Interference in Pathology

Indinavir (Sulphate) may interfere in the diagnosis of Increased serum cholesterol, Increased serum triglycerides.

Available Brands

None recorded.

Storage Conditions

Indinavir (Sulphate) should be stored Caps.

Drug Classification

1.6.5.2 — Antiretroviral drugs